Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Misses Expectations By $0.19 EPS

Keros Therapeutics (NASDAQ:KROS) announced its earnings results on Thursday. The company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19), FiscalAI reports. The firm had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 14.91%.

Keros Therapeutics Stock Performance

Shares of KROS opened at $10.50 on Friday. The company has a market capitalization of $207.80 million, a P/E ratio of -3.49 and a beta of 0.95. Keros Therapeutics has a one year low of $10.30 and a one year high of $22.55. The stock has a 50-day moving average price of $11.44 and a 200 day moving average price of $15.71.

Analyst Ratings Changes

A number of research firms have weighed in on KROS. Wells Fargo & Company decreased their price objective on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, March 5th. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $20.40.

Institutional Trading of Keros Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its position in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after purchasing an additional 1,888 shares during the period. New York State Common Retirement Fund raised its position in shares of Keros Therapeutics by 264.1% during the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after purchasing an additional 7,700 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Keros Therapeutics by 8.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares during the period. Sherbrooke Park Advisers LLC acquired a new stake in shares of Keros Therapeutics during the 3rd quarter worth approximately $176,000. Finally, XTX Topco Ltd bought a new position in Keros Therapeutics in the 4th quarter worth approximately $212,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.